A cross-talk between microbiota-derived short-chain fatty acids and the host mucosal 1 immune system regulates intestinal homeostasis and inflammatory bowel disease. 2 3
for development of obesity, asthma, allergies and immune deficiencies (11) . However, the 1 composition of microbiota community is rapidly evolving during the first year of life, when 2 Bifidobacterium is dominant, microbial diversity gradually increases, reaching an adult stable 3 configuration at age of 2-3 years (4) . During this evolution the host genetics can shape the 4 microbiome composition (12), but the environmental factors (e.g. dietary and antibiotic use) 5 have a major impact in shaping this community (4, 8) . The adult microbiota composition of C-6 section delivered babies is comparable to vaginally delivered (3, 13), suggesting that delivery 7 mode does not affect adult microbiota composition. Dietary and microbial antigens can also be 8 absorbed in the mucosa, transferred across the placenta from the mother blood to the fetus and 9 affect the development of fetal immune system. For example, maternal consumption of vitamin 10
A and subsequent generation of retinoic acid signalling is important for modulation of fetal 11 lymphoid tissue inducer (LTi) cell differentiation which impacts on the size of secondary 12 lymphoid organs and the efficiency of immune responses in the adult offspring (14) . 13
Metabolites produced by microbiota during late pregnancy protect also against the development 14 of allergic responses in adult offspring (15) . Recently, a study in pregnant mice colonized with 15 the bacteria that then returned to a germ-free (GF) state before giving birth, showed that 16 microbiota metabolites produced in pregnancy leads to increased numbers of group 3 innate 17 lymphoid cells (ILC3s) and intestinal mononuclear cells in gut of newborns (16). This increase 18 persisted until at least 8 weeks after birth, suggesting that temporary microbiota colonization 19 has long-term effects on the immune system. Maternally acquired antibodies during pregnancy 20 specific from commensal microbes can also regulate T helper (Th) cell activation in gut of 21 neonatal mice (17). Therefore, the exposure to various microbial antigens, metabolites and 22 antibodies in the fetus contributes to the early development of a functional immune system (7) . 23
These studies suggets that both prenatal (maternal) and the early life (infant) microbiota have 24 crucial roles in the development of immune system. 25
Decades of studies in GF animals showed that multiple microbial species have an 1 important role in the development of gut-associated lymphoid tissue (18) (19) (20) and in the 2 colonization of the gut wall by immune cells, such as the so-called intraepithelial lymphocytes 3 (21-24), lamina propria neutrophils (25) , dendritic cells (26), ILC3s (16, 27, 28), mucosal-4 associated invariant T (MAIT) cells (29, 30), TCR αβ Th17 cells and TCR γδ IL-17-producing 5 cells (31) (32) (33) , regulatory T cells (Tregs) (34) , and immunoglobulin (Ig)A secreting plasma cells 6 (35, 36). Moreover, the maturation of specific immune cells depends on certain host-specific 7 bacterial species (26). For example, particular bacteria have been linked to the development of 8
Th17 cells (37, 38) and others are involved in the expansion of Foxp + Tregs (34, 39) . Despite 9 these studies in mice there are no studies about the effect of microbiota in human cellular subset 10 composition (40) . However, human healthy individuals have high level of interindividual 11 variation in immune cell subset composition and the largest influence on immunological 12 variation identified was cohabitation, with 50% less immune cell variation between individuals 13 who share the same environment (41) . Microbiota composition may have a role, for example 14 cohabiting individuals show convergence in microbiomes (42, 43) possibly via direct 15 transmission (44). Microbiota protect also the host from opportunistic pathogenic infection (45, 16 46), since they inhibit the adhesion to the gut mucus and colonization by pathogens (47) . In 17 addition to this barrier effect, commensal microbiota produce bacteriocins and short chain fatty 18 acids (SCFAs), compounds that are able to inhibit the growth of potentially invading pathogenic 19 bacteria (47, 48). Louis Pasteur two centuries ago already said that "the role of the infinitely 20 small in nature is infinitely great". 21
22

MICROBIOTA AND THE GUT IMMUNE SYSTEM 23
Gut-associated lymphoid tissue (GALT), together with intestinal draining lymph nodes 24 (LNs), serve as the major sites of adaptive immune cell priming. Antigens sampled through M 25 cells are taken up by antigen-presenting cells for processing and presentation to lymphocytes 1 in gut-associated lymphoid tissue. In addition, some bacteria can directly colonize gut-2 associated lymphoid tissue (i.e. lymphoid follicles, Peyer's patches and the mesenteric lymph 3 nodes) in healthy mammals. (49-51). 4
The majority of adaptive immune cells in the epithelium are intraepithelial lymphocytes 5 (IELs) (52) . These cells are located between intestinal epithelial cells (IECs) in a ratio of 6 approximately one lymphocyte for every six to ten IECs (53). For example, small intestine 7 harbor ≈ 50 millions intraepithelial T lymphocytes (IELs) representing up to half the number 8 of T cells in the mice (54). IELs include conventional CD8 + and CD4 + αβ T cells, as well 9 unconventional T cell types including TCRγδ + and CD8αα + TCRαβ + lymphocytes (53). TCRγδ + 10 constitute a major proportion of the IELs population that contributes to the maintenance of the 11 epithelial barrier and gut homeostasis (53). Conventional TCRαβ + IELs derive from naïve T 12 cells that have undergone activation in GALT or LNs and subsequently homed to the intestine 13 to generate epithelial resident effector memory T cell population. Microbiota diversity induces 14 a progressive and considerable increase in the numbers of both CD8αβ + and CD8αα + TCRαβ + 15 IELs (26, 55, 56). The absence/reduction of CD8αβ + TCRαβ + IELs in GF mice (21-24) supports 16 a major role of the microbiota in the generation of these cells (22, 57, 58) . Underlying the 17 intestinal epithelium is the lamina propria. The most abundant immune population in the lamina 18 propria is macrophages, which rapidly phagocytize microbes that breach the gut physical 19 barrier.
These macrophages predominantly represent tissue-resident non-migratory 20 macrophages, belonging to the functional M2 subtype characterized by the production of large 21 amounts of IL-10. Besides macrophages, lamina propria is also rich in dendritic cells. These 22 cells can extend dendrites between IECs without disrupting the intestinal barrier function, 23 acquire antigens from microbiota and subsequently migrate to mesenteric lymph nodes, where 24 they are presented these antigens to T cells. In normal conditions, dendritic cells induce 25 tolerance to commensal microbiota antigens, through the secretion of TGF-β and retinoic acid 1 induces de differentiation of naïve CD4 + T cells in Tregs (59). 2 Part of the adaptive immune system, B cells are one of the predominant population in 3 the lamina propria of small intestine and colon (60). Was estimated that 80% of human and 4 mouse fully differentiated B cells (plasma cells) are located in the intestinal lamina propria. 5
One of the most prominent effects of microbiota colonization is the induction of secretory IgA 6 (35, 36). The switch of IgM-positive B cells to IgA-positive B cells occur mostly in GALT, a 7 T dependent and independent pathway, induce the production of IgA that is next secreted at the 8 epithelial level. IgA binds to surface molecules expressed by microbes causing their 9 agglutination in the gut lumen (61). High-affinity antigen-specific IgA, produced by a T 10 dependent pathway, binds to surface molecules expressed by pathogenic bacteria and their 11 toxins and helps in their neutralization (62-64). On the other hand, commensal bacteria might 12 also become coated with IgA but the level of these process is generally been believed to be 13 lower as compared to pathogenic bacteria (65). This is probably due to the fact that commensal 14 microbiota induces low-affinity IgA in a T cell independent manner, since mice lacking cognate 15 T-cell-B-cell interactions or mice lacking T cells still mount IgA responses to commensal (62-16
64). 17
Lamina propria is also rich in conventional αβ T cells, ≈ 15% of CD8 + and ≈ 85% of 18
CD4 + T cells in mice (38). CD4 + T cells in the lamina propria of small intestine and colon are 19
predominantly RORγt + Th17 cells and RORγt + Foxp3 + Tregs (66). RORγt + Th17 represents 20 40% of CD4 + T cells in the small intestinal (38) and about 50% in the colonic lamina propria 21
(67). Tregs represents 20% of CD4 + T cells in the small intestinal lamina propria and about 22
30% in the colonic lamina propria (68). Microbiota colonization is a prerequisite to gut 23 accumulation of both RORγt + Th17 cells (31, 67, 69) and Foxp3 + Tregs (34, 70, 71) . Microbiota 24 induces antigen-specific RORγt + Th17 cells responses in the gut (72), and these cells are also 25 essential for protection against opportunistic infections. On the other hand, Tregs suppress a 1 wide range of immune cells, maintain tolerance to environmental antigens and avoid the risk of 2 gut inflammation (73). These cells are characterized by the permanent expression of high levels 3
of the transcription factor Foxp3, which is considered to confer their suppressive phenotype 4 (74). The majority of Foxp3 + Tregs develop in the thymus -thymus-derived Tregs (tTreg) -, 5 alternatively naïve CD4 + T cells upon antigen exposure and in the presence of TGF-β and 6 retinoic acid can also be induced to express Foxp3, producing peripherally-induced Tregs 7 (pTregs) in extrathymic tissues (75). Some studies suggest that a substantial proportion of the 8 colonic Tregs arises extrathymically from antigen-specific interactions with the colonic 9 microbiota (34, 70, 71) . These pTregs express a unique subset of TCRs (which do not overlap 10 with the tTreg TCR repertoire) and recognized epitopes derived from commensal microbiota 11 (70, 71). 12
Innate lymphoid cells (ILCs) are resident innate cells in the lamina propria that share 13 functional characteristics with differentiated T cells. ILCs can be subdivided into three different 14 groups referred to as group 1, 2, and 3. Group 3 ILCs in mice is further categorized in CCR6 + 15
LTi cells and CCR6 − ILC3s cells, some CCR6 − ILC3 cells express a natural cytotoxicity-16 triggering receptor (NCR, NKp46) and others not. At the present time, ILC3s appears to be the 17 most dependent on the presence of microbes. Microbiota induces CCR6 + LTi cells that promote 18 the formation of secondary lymphoid organs (18) (19) (20) and NCR + ILC3s numbers (16, 27, 28) . 19
Both CCR6 + ILC3 cells and NCR + ILC3 cells are major producers of IL-22 and IL-17A, 20 cytokines that sustain epithelial integrity and regulate mucosal immunity (76). Microbiota 21 colonization stimulates IL-22 production by ILC3s (16, 27, 28). IL-22 maintains the intestinal 22 barrier function by promoting the production of antimicrobial peptides and mucus involved in 23 antimicrobial host defense, and promote wound healing, tissue remodeling and repair (28, 77, 24 78). IL-22 induces also fucosylated carbohydrate synthesis in IECs (79) and these 25 carbohydrates can supplies a selective advantage to beneficial commensal bacteria that can 1 metabolize these compounds (79, 80). On the other hand, IL-17 is essential for regulating 2 mucosal host defense against invading pathogens, and the disruption of this signaling in the gut 3 epithelium results in microbiota dysbiosis (81). ILC3s have other important functions, namely 4 MHCII + ILC3s reduce commensal-specific Th responses by the antigens presentation and 5 induction of a CD4 + T cells negative selection process (82). In addition, ILC3-mediated release 6 of granulocyte/macrophage colony-stimulating factor via IL-1β maintains colonic Tregs 7 homeostasis (83). Furthermore, ILC3-derived lymphotoxins orchestrate IgA secretion and 8 control microbial composition in the gut (84). All of these properties makes that ILC3s 9 depletion promotes the dissemination of bacteria in gut and drive systemic inflammation (28, 10 49, 85). 11
12
MICROBIOTA AND SHORT CHAIN FATTY ACIDS 13
The innate immune cells and non-immune cells of the host receive direct stimulus from 14 the microbial antigens through microbe-associated molecular patterns (MAMPs), such as toll-15 like membrane receptors (TLRs) and intracellular nucleotide-binding oligomerization domain 16
(NODs). The continuous intestinal absorption of low-level microbial products such as NODs 17
and TLRs ligands, microbial antigens into the systemic circulation represents a crucial aspect 18 of the cross-talk between the microbiota and the systemic immune system (45). For example, 19 bone marrow progenitor cells can directly sense microbiota signals (e.g. LPS) via TLRs (86) 20 and microbiota can control immunity through regulation of hematopoiesis at primary immune 21 sites (87). Indeed, GF mice display reduced proportions and differentiation potential of specific 22 myeloid progenitors cells, have decrease resident myeloid cell populations in bone marrow and 23 reduction of in monocytes, macrophages and neutrophils in peripheral sites (87). On the other 24 hand, microbiota colonization can enhance myelopoiesis and increase the myeloid cells in 25 peripheral sites (87). Microbiota can also affect TCRαβ + CD8 + and CD4 + T cells, TCRγδ + and 1 ILCs in other peripheral sites (e.g. lymph nodes, lung, skin and brain) (88, 89) and regulate 2 immune responses in peripheral sites (e.g. in pancreas (90) and brain (89)). 3
Commensal microbial metabolism produces essential vitamins (e.g. group B and K 4 vitamins), SCFAs as well metabolizes compounds (e.g. bile acids, sterols and xenobiotics) that 5 are transformed into secondary bioactive metabolites and contribute to the gut "metabolome" 6 (4, 91). Besides structural components of bacteria, many of metabolites derived from 7 commensal microbial metabolism have been implicated in the development and function of 8 immune cells, e.g. vitamin B-based metabolites in MAIT cells (30, 92) and sphingolipids in 9
invariant Natural Killer T (iNKT) cells (93). However, the best-studied microbial metabolites 10 that influences immune system homeostasis are SCFAs, in particular acetate, propionate and 11 butyrate (BT) ( Figure 1 ). Moreover, the most abundant commensal bacteria in gut, 12
Bacteroidetes and Firmicutes, are able to ferment non-digestible carbohydrates releasing 13 SCFAs (94) that can be found at high concentrations in healthy gut (e.g. 20 mM BT in colonic 14 lumen) (95). Among SCFAs, BT has multiple regulatory roles at gut level, exerting an anti-15 inflammatory effect on both intestinal epithelial cells and immune cells (96, 97). This article 16 highlights our current understanding of how SCFAs, specifically BT, interact with immune cell 17 generation, trafficking, and function, and how these interactions influence host gut health 18 ( Figure 1 ). SCFAs produced by the microbiota can also translocate from the gut to the 19 bloodstream and regulate host systemic immune system (88). For example, SCFAs can inhibit 20 hematopoiesis and inducing accumulation of immature dendritic cells in bone marrow (87, 98), 21 can increase Tregs in lungs (15) and protect against the development of lung allergic 22 inflammation (15, 98, 99). SCFAs are also key molecules that modulate microglia (the brain's 23 macrophages) maturation, morphology and function (100) and can attenuate 24 neuroinflammation (101). 25 1
SCFA CROSSTALK WITH THE INTESTINAL EPITHELIUM 2
The intestinal barrier is a functional entity separating the gut lumen (and microbiota) 3 from the host. Several elements participate in this barrier including a single monolayer of 4 polarized IECs, represented by absorptive enterocytes, mucus-secreting goblet cells, hormone-5 producing enteroendocrine cells, and antimicrobial peptides and lectins-secreting Paneth cells 6 (102). IECs secrete mucus and antimicrobial proteins (e.g. C-type lectin RegIII-β and RegIII-7 γ) and BT increase the expression of mucins (103) and anti-microbial peptides (104, 105) in 8
IECs. Interestingly enough, BT leads to IECs inflammasome activation and production of anti-9 inflammatory IL-18 (106, 107), a cytokine involved in mucins and anti-microbial peptide 10 production and in the control of gut microbiota composition (108). Additionally, BT promotes 11
intestinal barrier function due to its ability to suppresses intestinal stem cell proliferation (109), 12 promote crypt IECs differentiation and modulation of the expression of tight junction proteins 13 (110, 111). IECs modulate also IgA transcytosis to gut lumen that when bound to specific 14 bacteria causes their agglutination and anchorage to the mucus, preventing their direct contact 15 with the epithelium (102). SCFAs added to parenteral nutrition increases secretory IgA levels 16
in the intestinal mucosa of mice (112). It is known that IECs supports IgA class switching (113). 17
BT induces the expression of TGF-β in IECs (39), and TGF-β indirectly induces B cell class 18 switching to produce IgA (64). In addition, SCFAs regulate directly the metabolism and gene 19 expression in B cells and promotes the secretion of IgA (114, 115) . This data suggests that BT 20 induction of secretory IgA is a T cell independent mechanism to maintain control the 21 commensal microbiota composition (115, 116). 22
IECs not only physically separate the luminal contents from the internal milieu but also 23 mediate the cross-talk between the microbiota and the immune cells in the lamina propria (117) . 24
This communication is mediated via cell-cell contact (with T cells and dendritic cells) and 25
chemokine and cytokine signaling. IECs can produce some cytokines (e.g. IL-10 and TGF-β) 1 that affect immune cells (118-120) and respond to cytokines and other mediators produced by 2 immune cells in the lamina propria (117) ( Figure 1 ). IECs receive direct stimulus from the 3 microbial antigens through (TLR)1-5 and 9 and NOD2 (121). The activation of these receptors 4
induces the production of proinflammatory cytokines (122) and chemotactic factors for both 5 myeloid and lymphoid cells (123). However, IECs express low levels of TLRs on the apical 6 side (pole facing the intestinal lumen) and higher levels on the basolateral side (that 7 communicates with lamina propria), being essentially stimulated by invasive bacteria (121). 8
Interestingly, BT decreases TLR4 expression and production of proinflammatory cytokines in 9
IECs (124, 125). On the other hand, proinflammatory cytokines can drive the expression of 10 neutrophil chemoattractant chemokines in IECs (126), such as IL-8, a chemokine that BT can 11 significant decrease the secretion (124, 127). BT was also shown to inhibit the expression of 12 the chemokines CXCL5 and CXCL11 (128). In conclusion, BT has a direct anti-inflammatory 13 effect on IECs and in the crosstalk between IECs and gut immune cells. 14
15
SCFA CROSSTALK WITH THE IMMUNE SYSTEM 16
Understanding the complex molecular mechanisms underlying the anti-inflammatory 17 effect of SCFAs, specifically BT, has been difficult because they interact with multiple 18 signaling molecules. First, BT was demonstrated to be a physiologic ligand of membrane G-19 protein-coupled receptors GPR109A (129), GPR41 and GPR43 (130-132). GPR109A are not 20 activated by propionate and acetate. However, acetate can activate GPR43 and propionate both 21 GPR41 and GPR43, altought with different affinities (129-132). GPR109A is a receptor 22 expressed by some immune cells (e.g. macrophages, dendritic cells and neutrophils) and the 23 activation of this receptor decrease the production proinflammatory mediators (133, 134). 24 GPR41 and GPR43 are also expressed by some immune cells such as monocytes, dendritic 25 cells, eosinophils and neutrophils (130, 131, 135-138). At least GPR43 seems to be important 1 in the regulation of immune responses, since mice lacking GPR43 develop exacerbated 2 inflammation in models for colitis due to higher production of inflammatory mediators and 3 increased recruitment of immune cells (135, 136). SCFAs uptake inside the immune cells is HDACi activity stimulates thymic production of tTregs and increases their peripheral numbers 24 in normal mice (174). BT can also increase tTregs numbers in colon (138). The oral 25 administration of SCFAs can mediate the migration of tTregs into the gut through the 1 upregulation of GPR15 receptor, a receptor implicated in the homing of mice tTregs in colon 2 (138, 175, 176). GPR43 and GPR41 receptors are also expressed in leukocytes (130, 137). 3
SCFAs induced lung Tregs suppressor function by a GPR41-dependent manner (177), 4
suggesting that these receptors may have a chemoattractant effect for Tregs. 5 6
Decrease in proinflammatory mediators 7
Macrophages through the secretion of cytokines can control the inflammatory state of 8 the gut (178). The activation and production of proinflammatory cytokines by macrophages is 9 regulated by histone modifications (179, 180). Therefore, BT acting as a HDACi, inhibits 10 macrophages-mediated production of proinflammatory mediators (e.g. TNF-α, IL-6) in vitro 11
(181, 182) and in vivo (94, 181). In addition, BT induces their apoptosis (183) decreasing the 12 number of proinflammatory M1 macrophages in vivo (145, 181). Dendritic cells are also able 13
to drive inflammatory T cell responses in gut. However, BT decreases dendritic cell co-14 stimulatory molecules (184, 185), decreases their activation (107) and suppresses the 15 production of Th1 cytokines (e.g. TNF-α, IL-1β, IL-8) (180, 184, 186). Neutrophils can also 16 release multiple proinflammatory mediators (187) . BT reduces the production of 17 proinflammatory cytokines (e.g. TNF-α and cytokine-induced neutrophil chemoattractant-2) in 18 neutrophils (136, 173, 188), decreases their phagocytosis capacity and cytotoxic effect (189-19 193) . BT can induce apoptosis (194) and the induction of apoptosis might be involved the 20 observed decrease of neutrophil numbers in vivo (195) . Mast cells are also traditionally 21 associated with inflammation. However, BT through HDACi activity has been shown to 22 inhibits cell proliferation, increases cell apoptosis and suppress mast cell proinflammatory 23 cytokines production (196) . 24
The activation of naïve T cells requires presentation of antigens to T cells by antigen 1 presenting cells and, as described above, BT modifies the biology of antigen presenting cells. 2 Therefore, BT inhibits T cell activation (197) in response to antigens (197, 198) CD4 + T cells and inhibits the production of Th1 (197, 198, 213, 214) and Th17 cytokines (163, 18 215). These data suggest that BT can inhibit the activation and production of proinflammatory 19 cytokines. 20 21
Increase in anti-inflammatory mediators 22
Commensal microbiota, particularly the Firmicutes (Clostridium clusters IV and XIVa) 23
and Bacteroides fragilis are potent inducers of pTregs differentiation (34, 39) . These bacteria 24 are also major producers of SCFAs (34, 39 has also been shown Clostridium species produce SCFAs from butyrylated high-amylose diet 5 and induced specifically RORγt + Tregs in mouse colon lamina propria (67). However, in 6
another study, SCFAs was quantified by liquid chromatography-mass spectrometry (LC-MS) 7
in cecal content and they did not found correlation between SCFAs levels in gut and RORγt + 8
Treg frequency (69), most probably because SCFAs are efficiently and quickly absorbed from 9 gut lumen to IECs (110). Butyrylated starches are chemically modified starches, in which the 10 acyl group is linked to the starch framework by an ester bond, found to be used by colonic 11 bacteria that deliver esterified BT and propionate that leads to changes in gut microbiota 12 composition. Therefore, normal dietary resistant and butyrylated starches can have different 13 effects on microbiota profiles and in the induction of RORγt + Tregs. The induced RORγt + 14 pTregs have high levels of IL-10 production, a stable regulatory function even in inflammatory 15 conditions, (219) and can regulate Th1, Th2 and Th17 cell responses (69, 220). RORγt + Tregs 16 are mostly negative for neuropilin-1 (Nrp1) and Helios expression and are not present in GF 17 conditions (67, 69, 219). Another question arising from these studies is whether the Foxp3 + 18
Tregs induced by BT are antigen-specific. BT promotes the differentiation of colonic OVA-19 specific OT-II Foxp3 + T cells following the adoptive transfer of naïve OT-II CD4 + T cells and 20 oral administration of OVA antigen (107, 209). On the other hand, the administration of BT 21 failed to increase colonic Tregs in GF mice, suggesting that for the induction of pTregs naïve 22
CD4 + cells need to recognize bacterial antigens (67, 69, 209). Therefore, Foxp3 expression 23 needs to synergize with TCR signals to the generation of functional pTregs (221) and BT only 24 "burst" the conversion and expansion of antigen-specific Foxp3 + pTregs. 25 (235) and production of Th2 cytokines, such as IL-10 (138, 188) and IL-5 (236). The anti-24 inflammatory microenvironment can inhibit the expression of costimulatory molecules, MHCII 25 levels and proinflammatory cytokine production in dendritic cells, inducing tolerogenic 1 dendritic cells (237). Recently, it has been shown that SCFAs stimulate intestinal epithelial 2 cells to induce mucosal tolerogenic CD103 + dendritic cells (238). On the other hand, 3 tolerogenic dendritic cells can induce Foxp3 + Tregs, Tr1 cells and Bregs cells that produce the 4 immunosuppressive cytokines (237). ILC3s play also a key role in regulation of gut 5 homeostasis. BT promotes the production of retinoic acid in IECs (239) and dendritic cells 6 (107) that is important for modulation of ILC3s differentiation (14) . On the other hand induces 7 the production of TGF-β (39) that control ILCs plasticity (240, 241). Unpublished data suggest 8
BT as a modulator of ILCs and that the regulation of ILCs by BT was associated with 9 maintaining gut homeostasis (242). 10
In conclusion, the adult gut immune system may tolerate self and harmless non-self 11 antigens such as commensal microbiota, while maintaining the ability to recognize and induce 12 a robust proinflammatory response against pathogenic bacteria. Understanding how the gut 13 immune system discriminates between commensals and pathogens is a major challenge, active role in modulating the mucosal immune system to establish a ''tolerant'' phenotype 20 against beneficial commensal microbiota (Figure 1 ). Thus, high levels of BT tends to limit 21 immune responses towards the commensals and contribute to the maintenance of microbiota 22 
CONCLUSIONS AND FUTURE PROSPECTS FOR THERAPY 14
The relationship between microbiota dysbiosis and IBD is complex and dynamic, rather 15 than one of simple cause-effect. Studies attempting to determine whether microbiota dysbiosis 16 is truly causative or merely a consequence of inflammation in humans, have suffered from a 17 number of limitations, making it difficult to have definitive conclusions. However, IBD patients 18 have microbiota dysbiosis with reduced numbers of SCFAs-producing bacteria and reduced 19 concentration of BT in the gut. BT mediates increase in anti-inflammatory cells (e.g. Tregs, Tr1 20 and Bregs) and decreases proinflammatory mediators (e.g macrophages, dendritic cells 21 neutrophils and effector T cells) in gut, suggesting that microbiota dysbiosis and reduced gut 22
BT concentration are involved in the pathogenesis of IBD. Already in early 1900, commensal 23 microbes have been demonstrated to have beneficial properties in the host, and Ilya Mechnikov 24 had proposed the use of live microbes to maintain gut health and prolong life. Therefore, 25 probiotic supplementation (e.g. orally administered capsules with BT producing bacteria) and 1 modulation of diet (increased prebiotics -fiber) can be one option to treat IBD patients. Another 2 option for manipulation of the gut microbiota involves fecal microbiota transplantation (FMT) 3 from healthy donors to IBD patients (304). Interestingly enough, the richness of donor 4 microbiota with BT-producing bacteria is correlated with successes of FMT (305). Given its 5 anti-inflammatory effect, BT have been proposed to be used in IBD therapy (306). However, 6
the patenting of a natural product has an adverse impact on its clinical development. Some 7 structural analogs of BT were developed, e.g. Tributyrin (307) and AN-9 (308), and some 8 strategies are currently being developed to improve bioavailability of these compounds to use 9 in clinical trials (307, 309). 10
11
To end with Louis Pasteur: "Gentlemen, it is the microbes who will have the last word". 12
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LIST OF ABBREVIATIONS 20
BT -butyrate 21
CD -Crohn's disease 22
FMT -fecal microbiota transplantation 23
GALT -gut-associated lymphoid tissue 24
GF -germ-free 25
GPR -G-protein-coupled receptor 26
HDACi -histone deacetylases inhibitor 27
IBD -inflammatory bowel disease 1
IEC -intestinal epithelial cell 2
Ig -immunoglobulin 3
ILC3s -group 3 innate lymphoid cells 4
LNs -lymph nodes 5
LTi -lymphoid tissue inducer 6
MAIT -mucosal-associated invariant T cells 7
MAMP-microbe-associated molecular pattern 8
MCTs -monocarboxylate transporters 9
NF-κB -nuclear factor-kappa B 10
NODs -nucleotide-binding oligomerization domain 11
Nrp1-neuropilin-1 12
SCFAs -short-chain fatty acids 13 SMCT1 -sodium-coupled monocarboxylate transporter 1 14
Th -T-helper 15
TLR -toll-like membrane receptors 16
Tr1-CD4 + Foxp3 -IL10 + 17 This homeostasis is disrupted in inflammatory bowel disease (IBD) patients that have 17 frequently infections with some opportunistic pathogens and microbiota dysbiosis, i.e. reduced 18 numbers of SCFAs-producing bacteria and reduced concentration of BT in the gut. This has 19 been linked to a marked increase in the number of proinflammatory immune cells in the gut 20 mucosa of these patients, suggesting that reduced gut BT concentration may be involved in IBD 21 pathogenesis. 22 
